These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 24721392)

  • 1. Active glucagon-like peptide 1 quantitation in human plasma: a comparison of multiple ligand binding assay platforms.
    Fraser S; Dysinger M; Soderstrom C; Kuhn M; Durham R
    J Immunol Methods; 2014 May; 407():76-81. PubMed ID: 24721392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bioanalytical methods for the quantitation of PEGylated human insulin.
    de Dios K; Manibusan A; Marsden R; Pinkstaff J
    J Immunol Methods; 2013 Oct; 396(1-2):1-7. PubMed ID: 23933323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four distinct detection platforms using multiple ligand binding assay formats.
    Soderstrom CI; Spriggs FP; Song W; Burrell S
    J Immunol Methods; 2011 Aug; 371(1-2):106-13. PubMed ID: 21749873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies.
    Bak MJ; Wewer Albrechtsen NJ; Pedersen J; Knop FK; Vilsbøll T; Jørgensen NB; Hartmann B; Deacon CF; Dragsted LO; Holst JJ
    Diabetes Obes Metab; 2014 Nov; 16(11):1155-64. PubMed ID: 25041349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [GLP-1 (glucagon-like peptide 1)].
    Matsuyama T; Komatsu R
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():496-8. PubMed ID: 16149560
    [No Abstract]   [Full Text] [Related]  

  • 7. Bioanalytical platform comparison using a generic human IgG PK assay format.
    Leary BA; Lawrence-Henderson R; Mallozzi C; Fernandez Ocaña M; Duriga N; O'Hara DM; Kavosi M; Qu Q; Joyce AP
    J Immunol Methods; 2013 Nov; 397(1-2):28-36. PubMed ID: 23994108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an ultra-sensitive Simoa assay to enable GDF11 detection: a comparison across bioanalytical platforms.
    Myzithras M; Li H; Bigwarfe T; Waltz E; Gupta P; Low S; Hayes DB; MacDonnell S; Ahlberg J; Franti M; Roberts S
    Bioanalysis; 2016 Mar; 8(6):511-8. PubMed ID: 26917343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Multiple Immunoassay Technology Platforms to Select the Anti-Drug Antibody Assay Exhibiting the Most Appropriate Drug and Target Tolerance.
    Collet-Brose J; Couble PJ; Deehan MR; Nelson RJ; Ferlin WG; Lory S
    J Immunol Res; 2016; 2016():5069678. PubMed ID: 27243038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects.
    Jiménez A; Casamitjana R; Flores L; Delgado S; Lacy A; Vidal J
    Ann Surg; 2013 May; 257(5):894-9. PubMed ID: 23579541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon.
    Sloan JH; Siegel RW; Ivanova-Cox YT; Watson DE; Deeg MA; Konrad RJ
    Clin Biochem; 2012 Dec; 45(18):1640-4. PubMed ID: 22890005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active glucagon-like peptide-1 (GLP-1): storage of human plasma and stability over time.
    Di Marino L; Griffo E; Maione S; Mirabella M
    Clin Chim Acta; 2011 Aug; 412(17-18):1693-4. PubMed ID: 21600891
    [No Abstract]   [Full Text] [Related]  

  • 17. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of glucagon-like peptide 1; what to measure?
    Heijboer AC; Frans A; Lomecky M; Blankenstein MA
    Clin Chim Acta; 2011 Jun; 412(13-14):1191-4. PubMed ID: 21414305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes.
    Lund A; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
    Am J Physiol Endocrinol Metab; 2011 Jun; 300(6):E1038-46. PubMed ID: 21386059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A homogeneous enzyme fragment complementation cyclic AMP screen for GPCR agonists.
    Golla R; Seethala R
    J Biomol Screen; 2002 Dec; 7(6):515-25. PubMed ID: 14599349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.